The du­velis­ib hot pota­to is tossed to a new own­er as Ve­rastem looks to re­or­ga­nize around the pipeline

When In­fin­i­ty put up du­velis­ib for a no-mon­ey-down in­stant deal, the biotech was look­ing for a quick ex­it from a clin­i­cal dis­as­ter. Ab­b­Vie had walked away from their al­liance af­ter look­ing at how the da­ta stacked up in a crowd­ed field.

And while it was ap­prov­able, it wasn’t look­ing pret­ty to any­one who thought in com­mer­cial terms.

One Big Phar­ma’s trash, though, was seen as a biotech trea­sure as a deeply trou­bled Ve­rastem stepped up to grab the PI3K-delta/gam­ma — promis­ing to run it across the goal lines at the FDA. And they did just that, on­ly with lit­tle to show for it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER